Artelo Biosciences Inc.

$ARTL is up over 200% after they announced positive results from its first-in-human Phase 1 Single Ascending Dose (SAD) study of ART26.12, a novel non-opioid pain treatment candidate.

Share this article:

About the Author:

Artelo Biosciences Inc.

Joey Ramson

PRISM Market View Alerts

Get your dose of PRISM Market
View news, right in your inbox

Mailchimp Signup